Armstrong Says FDA "Assured" OTC Access Of Reformulated Primatene Mist
This article was originally published in The Tan Sheet
Executive Summary
Armstrong Pharmaceuticals says FDA "assured" the firm that it can sell a proposed reformulated epinephrine inhaler OTC, if approved, despite opponents who say asthma relief is an inappropriate self-medication indication